JP2023517934A5 - - Google Patents
Info
- Publication number
- JP2023517934A5 JP2023517934A5 JP2022554473A JP2022554473A JP2023517934A5 JP 2023517934 A5 JP2023517934 A5 JP 2023517934A5 JP 2022554473 A JP2022554473 A JP 2022554473A JP 2022554473 A JP2022554473 A JP 2022554473A JP 2023517934 A5 JP2023517934 A5 JP 2023517934A5
- Authority
- JP
- Japan
- Prior art keywords
- viral vector
- gene therapy
- transgene
- col4a4
- col4a5
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2003618.2A GB202003618D0 (en) | 2020-03-12 | 2020-03-12 | Gene Therapy |
| GB2003618.2 | 2020-03-12 | ||
| PCT/GB2021/050633 WO2021181118A1 (en) | 2020-03-12 | 2021-03-12 | Gene therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023517934A JP2023517934A (ja) | 2023-04-27 |
| JP2023517934A5 true JP2023517934A5 (https=) | 2024-03-21 |
Family
ID=70453740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554473A Pending JP2023517934A (ja) | 2020-03-12 | 2021-03-12 | 遺伝子治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12589167B2 (https=) |
| EP (1) | EP4118216A1 (https=) |
| JP (1) | JP2023517934A (https=) |
| CN (2) | CN121950927A (https=) |
| AU (1) | AU2021234169A1 (https=) |
| BR (1) | BR112022018036A2 (https=) |
| CA (1) | CA3171232A1 (https=) |
| GB (1) | GB202003618D0 (https=) |
| IL (1) | IL296255A (https=) |
| MX (1) | MX2022011295A (https=) |
| WO (1) | WO2021181118A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202003618D0 (en) | 2020-03-12 | 2020-04-29 | Univ Bristol | Gene Therapy |
| EP4273243A1 (en) | 2022-05-02 | 2023-11-08 | Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca | Nucleic acid constructs and vectors for podocyte specific expression |
| GB202304841D0 (en) * | 2023-03-31 | 2023-05-17 | Purespring Therapeutics Ltd | Promoter |
| CN116590345B (zh) * | 2023-05-06 | 2024-01-30 | 北京中医药大学 | 永生化小鼠足细胞系及其制备方法、分化方法和应用 |
| GB202309909D0 (en) * | 2023-06-29 | 2023-08-16 | Purespring Therapeutics Ltd | Regulatory elements |
| GB202309908D0 (en) * | 2023-06-29 | 2023-08-16 | Purespring Therapeutics Ltd | Polynucleotides, aav vectors, and pharmaceutical compositions for treating complement-mediated kidney diseases |
| GB202309913D0 (en) * | 2023-06-29 | 2023-08-16 | Purespring Therapeutics Ltd | Polynucleotides, avv vectors, and pharmaceutical compositions for treating nephrotic syndrome |
| GB202309914D0 (en) * | 2023-06-29 | 2023-08-16 | Purespring Therapeutics Ltd | Promoters |
| WO2025168940A1 (en) * | 2024-02-07 | 2025-08-14 | Purespring Therapeutics Limited | Vectors |
| WO2025193938A1 (en) * | 2024-03-13 | 2025-09-18 | Oregon Health & Science University | Delivery of type iv collagen alpha chain using a split intein dual aav vector |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT904392E (pt) | 1996-10-17 | 2001-06-29 | Oxford Biomedica Ltd | Vectores retrovirais |
| US20060281090A1 (en) | 2003-05-01 | 2006-12-14 | University Of Washington Uw Tech Transfer- Invention Licensing | Capsid-modified adenovirus vectors and methods of using the same |
| WO2005012351A2 (en) | 2003-08-01 | 2005-02-10 | The Brigham And Women's Hospital, Inc. | Novel functions for decay accelerating factor (daf) in inflammation |
| US7745389B2 (en) | 2005-02-14 | 2010-06-29 | University Of Iowa Research Foundation | Methods for treatment of age-related macular degeneration |
| WO2007056435A2 (en) | 2005-11-08 | 2007-05-18 | The General Hospital Corporation | Dynamin mediated diseases and associated methods and products |
| KR101105125B1 (ko) | 2007-05-07 | 2012-01-16 | 울산대학교 산학협력단 | 클러스터린을 이용한 체중 조절 장애 관련 질환의 진단, 예방 또는 치료 방법 |
| EP2730282A1 (en) | 2007-11-08 | 2014-05-14 | The General Hospital Corporation | Methods and compositions for the treatment of proteinuric diseases |
| US9279103B2 (en) | 2010-08-05 | 2016-03-08 | Wisconsin Alumni Research Foundation | Simplified basic media for human pluripotent cell culture |
| US8852936B2 (en) | 2012-09-21 | 2014-10-07 | Laurantis Pharma Oy | Autologous lymph node transfer in combination with VEGF-C or VEGF-D growth factor therapy to treat lymphedema and to improve reconstructive surgery |
| TW201506036A (zh) | 2013-08-14 | 2015-02-16 | Laurantis Pharma Oy | Vegf-c及ccbe1之治療用途 |
| WO2016014781A1 (en) | 2014-07-25 | 2016-01-28 | Rgdi3, Inc. | Collagen iv replacement |
| AU2017341849B2 (en) * | 2016-10-13 | 2024-03-21 | University Of Massachusetts | AAV capsid designs |
| CN107011424B (zh) | 2017-03-14 | 2020-07-03 | 华南师范大学 | 斜带石斑鱼补体c1inh基因、载体、重组菌株和蛋白及其应用 |
| GB201706808D0 (en) | 2017-04-28 | 2017-06-14 | Univ Newcastle | Modified complement proteins and uses thereof |
| CN118581154A (zh) | 2017-06-02 | 2024-09-03 | 国家健康与医学研究院 | 用于遗传障碍的基因疗法的基因组编辑手段和结合病毒载体的基因疗法 |
| EP3697920A4 (en) | 2017-10-20 | 2022-03-02 | Gemini Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION |
| RU2675861C1 (ru) | 2017-11-22 | 2018-12-25 | Лев Иосифович Шагам | Способ прогнозирования наличия мутации гена col4a5 у пациентов с предполагаемым диагнозом "синдром альпорта" |
| AU2019346335B2 (en) * | 2018-09-28 | 2024-07-25 | Massachusetts Institute Of Technology | Collagen-localized immunomodulatory molecules and methods thereof |
| CN113166208B (zh) * | 2018-10-02 | 2024-11-22 | 沃雅戈治疗公司 | 重新定向aav衣壳的嗜性 |
| CA3117551A1 (en) | 2018-10-23 | 2020-04-30 | Gemini Therapeutics Inc. | Compositions and methods for treating age-related macular degeneration and other diseases |
| RU2714763C1 (ru) | 2018-11-08 | 2020-02-19 | Генетик Диагностикс Энд Терапи 21 Лтд | Генотерапевтический ДНК-вектор для таргетной генной терапии, способ его получения (варианты), штамм для его производства, способ его получения |
| GB201900702D0 (en) | 2019-01-18 | 2019-03-06 | Univ Bristol | Therapy |
| GB202003618D0 (en) | 2020-03-12 | 2020-04-29 | Univ Bristol | Gene Therapy |
| GB202010009D0 (en) | 2020-06-30 | 2020-08-12 | Syncona Investment Man Ltd | Vector |
| GB202103470D0 (en) | 2021-03-12 | 2021-04-28 | Univ Bristol | Promoter |
-
2020
- 2020-03-12 GB GBGB2003618.2A patent/GB202003618D0/en not_active Ceased
-
2021
- 2021-03-12 EP EP21711944.5A patent/EP4118216A1/en active Pending
- 2021-03-12 CN CN202511847212.8A patent/CN121950927A/zh active Pending
- 2021-03-12 CN CN202180020240.6A patent/CN115427578B/zh active Active
- 2021-03-12 JP JP2022554473A patent/JP2023517934A/ja active Pending
- 2021-03-12 WO PCT/GB2021/050633 patent/WO2021181118A1/en not_active Ceased
- 2021-03-12 IL IL296255A patent/IL296255A/en unknown
- 2021-03-12 CA CA3171232A patent/CA3171232A1/en active Pending
- 2021-03-12 AU AU2021234169A patent/AU2021234169A1/en active Pending
- 2021-03-12 US US17/909,839 patent/US12589167B2/en active Active
- 2021-03-12 BR BR112022018036A patent/BR112022018036A2/pt unknown
- 2021-03-12 MX MX2022011295A patent/MX2022011295A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023517934A5 (https=) | ||
| JP2022517407A5 (https=) | ||
| FI3717636T3 (fi) | Adenoassosioidun viruksen kapsidivariantteja ja käyttö angiogeneesin estämisessä | |
| JP2019513794A5 (https=) | ||
| JP2019523648A5 (https=) | ||
| FI4206216T3 (fi) | Adenoassosioituneen viruksen kapsidimuunnoksia ja menetelmiä niiden käyttämiseksi | |
| JP2019194251A5 (https=) | ||
| JP2022141670A5 (https=) | ||
| SE504074C2 (sv) | Proteinberedning för subkutan, intramuskulär eller intradermal administrering | |
| JP2020203894A5 (https=) | ||
| JP2021503914A5 (https=) | ||
| JP2022535745A5 (https=) | ||
| JP2022516317A5 (https=) | ||
| JP2018527941A5 (https=) | ||
| JP2023534037A5 (https=) | ||
| JP2004501650A5 (https=) | ||
| JP2023503850A5 (https=) | ||
| Gruntman et al. | Bridging from intramuscular to limb perfusion delivery of rAAV: optimization in a non-human primate study | |
| JP2020527167A5 (https=) | ||
| JP2021500880A5 (https=) | ||
| IL321380A (en) | Adeno-associated viral vectors for the treatment of best disease | |
| JP2023510784A5 (https=) | ||
| Barbour | The balance of risk and benefit in gene-therapy trials | |
| JP2017530128A (ja) | 肝細胞増殖因子及びストローマ細胞由来因子１αを用いた末梢動脈疾患の予防または治療用組成物 | |
| JP2020535203A5 (https=) |